Supplementary Table 1. Statistical data after analyzing the role of Caf in GM-IVH in the short (P14) and the long (P70) term.

| Study                                      | Short term (p14)                                                                 | Long term (P70)                                                                 |
|--------------------------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|
| Distance travelled in the open field       | \([F(2,70)=1.59, p=0.211]\)                                                      |                                                                                |
| Time in rotarod                            | \([F(2,73)=1.60, p=0.209]\)                                                      |                                                                                |
| Maximum speed in rotarod                   | \([F(5,72)=0.906, p=0.482]\)                                                     |                                                                                |
| Swimming velocity in the MWM               | \([F(2,73)=2.70, p=0.074]\)                                                      |                                                                                |
| What paradigm in the NOD test              | \([F(5,200)=2.32, p=0.038; †p=0.014 vs. Control+Caf10, Control+Caf20 and Col+Caf10]\) |                                                                                |
| Where paradigm in the NOD test             | \([F(5,213)=1.28, p=0.278]\)                                                      |                                                                                |
| When paradigm in the NOD test              | \([F(2,209)=3.97, p=0.002; ††p<0.001 vs. Control, Control+Caf10, Col+Caf10 and Col+Caf20]\) |                                                                                |
| Time along acquisition phase of the MWM    | day 1 \([F(5,305)=1.72, p=0.128]\) day 2 \([F(5,307)=0.315, **p=0.009 vs. rest of the groups]\) | day 3 \([F(5,310)=2.52, †††p=0.029 vs. Control, Control+Caf10 and Control+Caf20]\) day 4 \([F(5,270)=5.050, ‡‡p<0.01 vs. Control and Control+Caf10]\) |
| Number of entrances in quadrant 2 in the retention 1 of the MWM | \([F(2,67)=5.88, p=0.004; †††p<0.003 vs. Control, Control+Caf10, Control+Caf20, Col+Caf10]\) |                                                                                |
| Number of entrances in quadrant 2 in the retention 2 of the MWM | \([F(2,65)=4.60, p=0.013; ††p=0.047 vs. Control+Caf10 and Control+Caf20]\) |                                                                                |
| Brain/body weight ratio                    | \([F(2,87)=4.24, †p=0.017 vs. Control, Control+Caf10 and Control+Caf20]\)       | \([F(2,93)=8.38, **p<0.01 vs. rest of the groups]\)                             |
| Cortex size                                | \([F(5,236)=3.30, p=0.038, **p<0.001 vs. rest of the groups, ††p<0.001 vs. Control+calf10]\) | \([F(2,187)=3.32, p=0.038, #p=0.007 vs. Control+Caf20, Col+Caf10 and Col+Caf20]\) |
| Hippocampus size                           | \([F(2,117)=0.117, p=0.890]\)                                                   | \([F(2,83)=0.779, p=0.453]\)                                                   |
| Ventricle size                             | \([F(2,107)=0.198, p=0.5]\)                                                     | \([F(2,163)=3.12, p=0.046; ††p<0.005 vs. Control, Control+Caf10, Col+Caf10]\) |
|                                | Control+CaF20, Col+CaF20 | Control+CaF20, Col+CaF20 |
|--------------------------------|---------------------------|---------------------------|
| Cortex NeuN/DAPI ratio         | [F(2,273)=9.53, p<0.001;  **p<0.01 vs. rest of the groups] | [F(2,2983)=4.45, p=0.012; **p<0.01 vs. rest of the groups] |
| SVZ NeuN/DAPI ratio            | P14 [F(2,420)=11.82, p<0.01;  **p<0.01 vs. rest of the groups] | [F(2,559)=0.351, p=0.704] |
| Cortex neurite curvature ratio  | [F(2,4048)=16.79, p<0.01;  **p<0.01 vs. rest of the groups, ††p<0.01 vs. Control, Control+CaF10 and Control+CaF20] | [F(2,3645)=2.65, p=0.071] |
| SVZ neurite curvature ratio     | F(2,1129)=7.27, p=0.001;  **p<0.01 vs. rest of the groups] | [F(2,1016)=0.269, p=0.765] |
| Cortex P-tau/ total tau ratio   | [F(2,30)=3.33, p=0.49;  ↓↓p=0.006 vs. Control and Control+CaF10] | [F(2,26)=0.016, p=0.984] |
| Striatum P-tau/total tau ratio  | [F(2,27)=0.031, p=0.970] | [F(2,25)=0.768, p=0.474] |
| Density of Ki67+ cells          | [F(2,94)=1.74 p=0.181] | [F(2,85)=0.023, p=0.977] |
| DCX burden                     | [F(2,95)=5.86, p=0.003;  ###p=0.004 vs. Control and Col+CaF20] | [F(2,83)=0.694, p=0.503] |
| DCX/ Ki67+ ratio               | [F(2,96)=0.00, p=1.00] | [F(2,84)=0.00, p=1.00] |
| Cortex hemorrhage burden       | [F(2,150)=4.27, p=0.016; ↑↑p=0.001 vs. Control, Control+CaF20 and Col+CaF20] | [F(2,153)=12.02, p<0.001, **p=0.001 vs. rest of the groups] |
| SVZ hemorrhage burden          | [F(2,73)=5.93, p=0.004, **p=0.003 vs. rest of the groups] | [F(2,71)=4.74, p=0.012, ††p=0.010 vs. Control, Control+CaF10, Control+CaF20 and Col+CaF20] |
| Cortex microglia burden        | [F(2,1814)=87.42, p<0.001, **p<0.01 vs. rest of the groups, ↑↑↑p<0.01 vs. Control+CaF20] | [F(2,2914)=6.22, p=0.002; ††p<0.01 vs. Control, Control+CaF10, Col+CaF10 and Col+CaF20] |
| SVZ microglia burden           | F(2,335)=12.11, p<0.001;  **p<0.01 vs. rest of the groups, ↑↑↑p<0.01 vs. Control+CaF20] | [F(2,547)=7.14, p=0.001; **p<0.01 vs. rest of the groups] |

**Supplementary Table 2.** Hemorrhage burden are limited by CaF treatment in the cortex and SVZ both in the short (P14) and the Long (P70) term.
**Supplementary Table 2.** Hemorrhage burden was ameliorated by Caf treatment in the cortex and the hippocampus in animals with GM-IVH.

|                    | Hemorrhage burden (% area affected) |   |   |
|--------------------|-------------------------------------|---|---|
|                    | Cortex                              | P14 | P70 | SVZ |
| Group              |                                     |     |     |     |
| Control            |                                     | 0.057±0.006 | 0.022±0.003 | 0.138±0.035 | 0.446±0.130 |
| Control+Caf10      |                                     | 0.066±0.006 | 0.036±0.003 | 0.279±0.050 | 0.451±0.231 |
| Control+Caf20      |                                     | 0.054±0.005 | 0.046±0.006 | 0.252±0.049 | 0.506±0.363 |
| Col                |                                     | 0.084±0.007 | 0.173±0.035** | 0.841±0.307** | 1.634±0.362†† |
| Col+Caf10          |                                     | 0.047±0.006 | 0.070±0.009 | 0.359±0.067 | 0.959±0.316 |
| Col+Caf20          |                                     | 0.061±0.03  | 0.055±0.009 | 0.162±0.054 | 0.524±0.120 |

Hemorrhage burden was increased in the cortex from animals with Col lesions. Caf treatment limited this situation in the short [F(2,150)=4.27, \( p=.016; \) \( \nabla\nabla p=0.001 \) vs. Control, Control+Caf20 and Col+Caf20]. In the long term, Caf treatment completely counterbalanced increased cortical hemorrhage burden [F(2,153)=12.02, \( p<0.001, **p=0.001 \) vs. rest of the groups]). Hemorrhage burden was also improved in the SVZ after Caf treatment at P14 [F(2,73)=5.93, \( p=0.004, **p=0.003 \) vs. rest of the groups]. By P70 Caf at the highest dose (20 mg/Kg/day) successfully reduced hemorrhage burden in the SVZ [F(2,71)=4.74, \( p=0.012, \nabla\nabla p=0.010 \) vs. Control, Control+Caf10, Control+Caf20 and Col+Caf20].